Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors
BackgroundGerm cell tumors (GCTs) represent a highly curable cancer. However, a small proportion of poor-risk patients can develop choriocarcinoma syndrome (CS) connected with acute respiratory distress syndrome (ARDS) with a high mortality rate. Our retrospective study aimed to determine the risk f...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.911879/full |
| _version_ | 1818235136719716352 |
|---|---|
| author | Katarina Rejlekova Katarina Rejlekova Katarina Kalavska Katarina Kalavska Katarina Kalavska Marek Makovnik Marek Makovnik Nikola Hapakova Nikola Hapakova Michal Chovanec Michal Chovanec Valentina De Angelis Jana Obertova Jana Obertova Patrik Palacka Patrik Palacka Zuzana Sycova-Mila Jozef Mardiak Jozef Mardiak Michal Mego Michal Mego Michal Mego |
| author_facet | Katarina Rejlekova Katarina Rejlekova Katarina Kalavska Katarina Kalavska Katarina Kalavska Marek Makovnik Marek Makovnik Nikola Hapakova Nikola Hapakova Michal Chovanec Michal Chovanec Valentina De Angelis Jana Obertova Jana Obertova Patrik Palacka Patrik Palacka Zuzana Sycova-Mila Jozef Mardiak Jozef Mardiak Michal Mego Michal Mego Michal Mego |
| author_sort | Katarina Rejlekova |
| collection | DOAJ |
| description | BackgroundGerm cell tumors (GCTs) represent a highly curable cancer. However, a small proportion of poor-risk patients can develop choriocarcinoma syndrome (CS) connected with acute respiratory distress syndrome (ARDS) with a high mortality rate. Our retrospective study aimed to determine the risk factors of poor-risk GCTs susceptible to CS development.Patients and MethodsUsing a computerized database and a systematic chart review, we identified the records of 532 patients with GCTs treated at the National Cancer Institute from 2000 to 2018. Ninety eligible patients with poor-risk GCTs based on IGCCCG classification were identified. All patients were treated with platinum-based induction chemotherapy. Clinicopathological variables were collected and analyzed in correlation with CS development.ResultsNine (10%) of 90 patients developed CS in a median of 1 day (1–9 days) after chemotherapy administration. All patients died shortly after the chemotherapy start with a median of 4 days (3–35 days) due to ARDS development. In univariate analysis, metastatic lung involvement ≥50% of lung parenchyma, choriocarcinoma elements in histology specimen, dyspnea, cough, hemoptysis, ECOG PS ≥2, weight loss, hemoglobin ≤100 g/l, and NLR ≥3.3 at the time of presentation were associated with CS development. In multivariate analysis, ECOG PS ≥2 and metastatic lung involvement ≥50% were independently associated with CS. All patients with these two characteristics developed CS, compared to 0% with zero or one of these factors (p < 0.000001).ConclusionsIn our study, we identified factors associated with CS development. These factors might improve the risk stratification of the patients susceptible to CS and improve their outcome. |
| first_indexed | 2024-12-12T11:49:11Z |
| format | Article |
| id | doaj.art-823de7803edb437490c82821e5272339 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-12T11:49:11Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-823de7803edb437490c82821e52723392022-12-22T00:25:22ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-06-011210.3389/fonc.2022.911879911879Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell TumorsKatarina Rejlekova0Katarina Rejlekova1Katarina Kalavska2Katarina Kalavska3Katarina Kalavska4Marek Makovnik5Marek Makovnik6Nikola Hapakova7Nikola Hapakova8Michal Chovanec9Michal Chovanec10Valentina De Angelis11Jana Obertova12Jana Obertova13Patrik Palacka14Patrik Palacka15Zuzana Sycova-Mila16Jozef Mardiak17Jozef Mardiak18Michal Mego19Michal Mego20Michal Mego212nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, SlovakiaTranslational Research Unit, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaRadiology Department, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, Slovakia2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, SlovakiaOncology Department, National Cancer Institute, Bratislava, SlovakiaTranslational Research Unit, Faculty of Medicine, Comenius University, National Cancer Institute, Bratislava, SlovakiaBackgroundGerm cell tumors (GCTs) represent a highly curable cancer. However, a small proportion of poor-risk patients can develop choriocarcinoma syndrome (CS) connected with acute respiratory distress syndrome (ARDS) with a high mortality rate. Our retrospective study aimed to determine the risk factors of poor-risk GCTs susceptible to CS development.Patients and MethodsUsing a computerized database and a systematic chart review, we identified the records of 532 patients with GCTs treated at the National Cancer Institute from 2000 to 2018. Ninety eligible patients with poor-risk GCTs based on IGCCCG classification were identified. All patients were treated with platinum-based induction chemotherapy. Clinicopathological variables were collected and analyzed in correlation with CS development.ResultsNine (10%) of 90 patients developed CS in a median of 1 day (1–9 days) after chemotherapy administration. All patients died shortly after the chemotherapy start with a median of 4 days (3–35 days) due to ARDS development. In univariate analysis, metastatic lung involvement ≥50% of lung parenchyma, choriocarcinoma elements in histology specimen, dyspnea, cough, hemoptysis, ECOG PS ≥2, weight loss, hemoglobin ≤100 g/l, and NLR ≥3.3 at the time of presentation were associated with CS development. In multivariate analysis, ECOG PS ≥2 and metastatic lung involvement ≥50% were independently associated with CS. All patients with these two characteristics developed CS, compared to 0% with zero or one of these factors (p < 0.000001).ConclusionsIn our study, we identified factors associated with CS development. These factors might improve the risk stratification of the patients susceptible to CS and improve their outcome.https://www.frontiersin.org/articles/10.3389/fonc.2022.911879/fullchoriocarcinoma syndromeacute respiratory distress syndromegerm cell tumorspoor-riskinduction chemotherapyhuman choriogonadotropin |
| spellingShingle | Katarina Rejlekova Katarina Rejlekova Katarina Kalavska Katarina Kalavska Katarina Kalavska Marek Makovnik Marek Makovnik Nikola Hapakova Nikola Hapakova Michal Chovanec Michal Chovanec Valentina De Angelis Jana Obertova Jana Obertova Patrik Palacka Patrik Palacka Zuzana Sycova-Mila Jozef Mardiak Jozef Mardiak Michal Mego Michal Mego Michal Mego Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors Frontiers in Oncology choriocarcinoma syndrome acute respiratory distress syndrome germ cell tumors poor-risk induction chemotherapy human choriogonadotropin |
| title | Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors |
| title_full | Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors |
| title_fullStr | Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors |
| title_full_unstemmed | Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors |
| title_short | Factors Associated With Choriocarcinoma Syndrome Development in Poor-Risk Patients With Germ Cell Tumors |
| title_sort | factors associated with choriocarcinoma syndrome development in poor risk patients with germ cell tumors |
| topic | choriocarcinoma syndrome acute respiratory distress syndrome germ cell tumors poor-risk induction chemotherapy human choriogonadotropin |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.911879/full |
| work_keys_str_mv | AT katarinarejlekova factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT katarinarejlekova factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT katarinakalavska factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT katarinakalavska factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT katarinakalavska factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT marekmakovnik factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT marekmakovnik factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT nikolahapakova factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT nikolahapakova factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT michalchovanec factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT michalchovanec factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT valentinadeangelis factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT janaobertova factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT janaobertova factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT patrikpalacka factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT patrikpalacka factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT zuzanasycovamila factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT jozefmardiak factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT jozefmardiak factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT michalmego factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT michalmego factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors AT michalmego factorsassociatedwithchoriocarcinomasyndromedevelopmentinpoorriskpatientswithgermcelltumors |